Judith James, MD
Rheumatology · Oklahoma City, OKNPI 1871561068
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,660 of the $14,673 with a category attached, or 93.1%. 4 manufacturers reported payments, led by GSK at 57.7% of the total. Reporting peaked in 2022 at $5,003 and has fallen 50.4% since, to $2,482 in 2024.
Across 12 payments — averaging $1222.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$8K
- Novartis$5K
- Merck$490
- Bristol Myers Squibb$428
Across 4 payments — averaging $785.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3K
What the payments were for
- Consulting fees$13,66093%
- Food & beverage$1,0147%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 6 | $8,468 |
| Novartis | 3 | $5,288 |
| Merck | 2 | $490 |
| Bristol Myers Squibb | 1 | $428 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$8,468
How this compares
$14,673 in reported general payments places this provider in the 75th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 12 | $87,285 |
| XareltoRivaroxaban | 12 | $6,575 |
| Celecoxib | 56 | $4,356 |
| Hydroxychloroquine Sulfate | 84 | $3,367 |
| Cevimeline Hcl | 18 | $3,052 |
| Duloxetine Hcl | 47 | $1,896 |
| Aripiprazole | 35 | $1,068 |
| Gabapentin | 95 | $813 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 29 | $775 |
| Prednisone | 104 | $765 |
| Fentanyl | 13 | $741 |
| MethotrexateMethotrexate Sodium | 25 | $698 |
| Vilazodone Hcl | 11 | $657 |
| Ezetimibe | 12 | $552 |
| Eszopiclone | 24 | $465 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Oklahoma City
- Joan MerrillOklahoma City$864K
- Latisha HeinlenOklahoma City$675K
- Mohammad KhanOklahoma City$94K
- Cristina ArriensOklahoma City$82K
- John GoetzingerOklahoma City$18K
- Robert ArthurOklahoma City$16K
- Muhammad GillanOklahoma City$16K
- William SchnitzOklahoma City$15K
- Amanda TitusOklahoma City$13K
- Michael PickrellOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.